Search

everythinglearnresearchcommunity

for

Search:↓

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

Redensyl, Procapil, and capixyl are discussed as treatments for hair regrowth, with some users reporting cosmetic thickening and vellus hair growth. Others prefer using topical finasteride and minoxidil for better results.

The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

The user experienced side effects from various hair loss treatments, including RU58841, finasteride, and dutasteride. They are uncertain about what treatment to try next.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.

Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.